The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Key components of chemotherapy for thymoma and thymic carcinoma: Anthracycline-, carboplatin-, or cisplatin-based chemotherapy.
Yusuke Okuma
No relevant relationships to disclose
Yukio Hosomi
No relevant relationships to disclose
Kageaki Watanabe
No relevant relationships to disclose
Yoshiro Nakahara
No relevant relationships to disclose
Yusuke Takagi
No relevant relationships to disclose
Makoto Saito
No relevant relationships to disclose
Tatsuru Okamura
No relevant relationships to disclose